The time has come to "raise the bar" in cancer clinical trials.
Many patients believe that palliative chemo is curative treatment, so oncologists need to have important end-of-life discussions early in the course of cancer care.
Although dire predictions about the ruling on the biotech industry and health care have not come to pass, questions remain regarding the sequence-interpreting experience of the new crop of BRCA testing labs.
New optical technology is showing great promise in fighting cancer by targeting treatment but with minimal side effects to the patient.
A new study suggests that a noninvasive DNA stool test may enhance the efficacy of screening for colorectal cancer.
Although there are benefits to minimally invasive surgery, morcellation can increase the risk of tumor dissemination of uterine leiomyosarcomas.
Nanopharmaceutical formulations might allow newly widespread adoption of old anticancer agents, with reduced toxic effects.
Science presented at the 2014 Genitourinary Cancers Symposium focused on the clinical potential of prostate cancer biomarkers.
One recently published study found no mortality benefit to annual screening mammograms, but critics cry "foul."
HER2 screening and emetine dihydrochloride may offer patients with bladder cancer more effective treatment options.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|